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ARTICLE
Semimechanistic Population Pharmacokinetic Model to 
Predict the Drug–Drug Interaction Between S- ketamine 
and Ticlopidine in Healthy Human Volunteers
Muhammad W. Ashraf1, Marko A. Peltoniemi1,2, Klaus T. Olkkola3, Pertti J. Neuvonen4 and Teijo I. Saari1,2,*
Low- dose oral S- ketamine is increasingly used in chronic pain therapy, but extensive cytochrome P450 (CYP) mediated me-
tabolism makes it prone to pharmacokinetic drug- drug interactions (DDIs). In our study, concentration- time data from five 
studies were used to develop a semimechanistic model that describes the ticlopidine- mediated inhibition of S- ketamine bio-
transformation. A mechanistic model was implemented to account for reversible and time- dependent hepatic CYP2B6 inac-
tivation by ticlopidine, which causes elevated S- ketamine exposure in vivo. A pharmacokinetic model was developed with 
gut wall and hepatic clearances for S- ketamine, its primary metabolite norketamine, and ticlopidine. Nonlinear mixed effects 
modeling approach was used (NONMEM version 7.3.0), and the final model was evaluated with visual predictive checks and 
the sampling- importance- resampling procedure. Our final model produces biologically plausible output and demonstrates 
that ticlopidine is a strong inhibitor of CYP2B6 mediated S- ketamine metabolism. Simulations from our model may be used 
to evaluate chronic pain therapy with S- ketamine.
CPT Pharmacometrics Syst. Pharmacol. (2018) 7, 687–697; doi:10.1002/psp4.12346; published online on 10 September 
2018.
Opioid receptor agonists are effective pain therapeutics,1 
but their use is complicated by severe side effects. The 
so- called “opioid crisis”2 emphasizes the need to reduce 
opioid use and to search for ways to improve multimodal 
analgesia in pain therapy. Activation of N- methyl- D- 
aspartate (NMDA) receptors may play a crucial role in the 
pathogenesis of chronic pain,3 and, therefore, orally admin-
istered ketamine, a potent NMDA receptor antagonist, has 
been used to treat complex chronic pain.4 Orally admin-
istered ketamine undergoes extensive first- pass metabo-
lism, resulting in a bioavailability of ~17%.5 The N- oxidation 
to norketamine by hepatic cytochrome P450 (CYP)2B6 is 
the primary metabolic pathway of ketamine biotransforma-
tion,6 whereas CYP3A has also been reported to contrib-
ute to ketamine metabolism in humans.7 A recent in vitro 
study has shown that the fraction of ketamine metabolized 
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WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔  Ticlopidine is a potent mechanism- based inhibitor of 
hepatic CYP2B6 in humans, which leads to an ~2.1- fold 
rise in S- ketamine exposure and may cause problems in 
pain therapy.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔  How a semimechanistic approach could be used to 
predict mechanism- based DDI between a CYP2B6- 
substrate S- ketamine and ticlopidine.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔  The complex interaction between S- ketamine and 
ticlopidine can be accurately predicted with a mechanistic 
static model. In addition, the use of a semimechanistic 
nonlinear mixed effects modeling approach could accu-
rately fit the pharmacokinetic profiles of S- ketamine, nor-
ketamine, and ticlopidine.
HOW MIGHT THIS CHANGE DRUG DISCOVERY, 
DEVELOPMENT, AND/OR THERAPEUTICS?
✔  The mechanistic static model is a valuable resource for 
precisely predicting mechanism- based DDIs in popula-
tion modeling. The semimechanistic model developed in 
our study can be used to precisely dose S- ketamine in 
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by hepatic CYP2B6 is around 60%,8 and, hence, CYP2B6- 
inhibition can lead to a significant increase in S- ketamine 
exposure.9
Ticlopidine is a mechanism- based inhibitor of 
CYP2B6,10,11 with a dissociation constant (Ki) of 0.031 μM, 
indicating a high potency of ticlopidine toward CYP2B6 inhi-
bition. Ticlopidine has a complex nonlinear pharmacokinetic 
profile that has been recorded previously in several reports.12 
Ticlopidine is metabolized to 2- oxo- ticlopidine primarily in 
the liver by CYP2B6 and CYP2C19,13,14 and previous stud-
ies have indicated that ticlopidine half- life is increased after 
multiple dosing, suggesting an auto- inhibition of ticlopidine 
metabolism.12
Our previous drug- drug interaction (DDI) study in healthy 
human volunteers demonstrated that ticlopidine causes a 
significant 2.1- fold rise in systemic exposure of orally ad-
ministered S- ketamine after a 6- day ticlopidine predosing 
(250 mg b.i.d.).9 Itraconazole, a CYP3A enzyme inhibitor, 
had no significant effect on plasma concentrations of orally 
administered S- ketamine, indicating that the gut wall might 
not be a significant contributor in S- ketamine first- pass 
metabolism.
The information gained by a static approach of DDI mod-
eling or a noncompartmental analysis (NCA) is limited.15 
Time variant parameters, such as the full pharmacokinetic 
profile of the perpetrator and the respective metabolites, 
are ignored and the mechanistic description of the inhibi-
tion process is restricted. A semimechanistic population 
pharmacokinetic model provides an intuitive way to apply 
a dynamic approach to account for a time- varying inhibition 
process and sources of unexplained interindividual variabil-
ity (IIV) based on in vivo data, as highlighted previously.15–17
We have reanalyzed our S- ketamine data with the aim of 
developing a population pharmacokinetic model that could: 
(1) account for the complex metabolic processes, which con-
stitute the metabolism of S- ketamine to norketamine; (2) ade-
quately predict the concentration- time course of S- ketamine 
and its primary metabolite norketamine, and of ticlopidine; 
and (3) mechanistically account for the DDI between S- 
ketamine and ticlopidine and accurately predict the rise in S- 
ketamine plasma concentrations after ticlopidine predosing.
METHODS
Concentration- time data for S- ketamine, norketamine, and 
ticlopidine were gathered from five previously conducted 
placebo controlled, blinded, randomized, crossover stud-
ies.7,9,18–20 For our analysis, we pooled the data from pla-
cebo phases of S- ketamine administration. For the DDI 
model development, the complete dataset (i.e., placebo as 
well as inhibitor phase) was included from the study that 
investigated the DDI between S- ketamine and ticlopidine.9 
A summarized description of these studies with the study 
designs, sampling schemes, and the drug analysis are de-
scribed in Supplementary Information S1. The study pro-
tocols of all of these studies were approved by the ethics 
committee of the Hospital District of Southwest Finland and 
by the Finnish National Agency of Medicines, and were reg-
istered in the EudraCT clinical trials register.
Data analysis
Nonlinear mixed effects modeling was conducted with 
the NONMEM (version 7.3.0) software package (ICON 
Development Solutions, Ellicott City, MD21) aided with Perl- 
Speaks- NONMEM toolkit (PsN,22 version 4.6.0 or above), 
which was utilized to support the model development, ex-
ecution, and evaluation. RStudio (version 1.0.153 or above) 
using R23 (R Foundation for Statistical Computing, 2018; 
version 3.4.0 or above) was used for model diagnostics and 
graphical visualization.
Model development
The first- order conditional estimation with interaction 
method was applied to the data. Pharmacokinetic modeling 
was conducted in a sequential manner; first, a pharmacoki-
netic model for S- ketamine was built, after which we incor-
porated a pharmacokinetic model for the major metabolite, 
norketamine. A pharmacokinetic model for ticlopidine was 
Table 1 Drug constants and physiological parameter values used in the 






















































BPRATIO, blood to plasma ratio; CYP, cytochrome P450; fu, unbound drug 
fraction in the blood; fu,GW, unbound drug fraction in the gut wall; fm,CYP2B6, 
fraction of drug metabolized by CYP2B6; kdeg, the de novo physiological 
rate of degradation of CYP2B6; ki, the equilibrium dissociation constant of 
ticlopidine for CYP2B6; KI, the inhibitor concentration half maximal inacti-
vation rate; Kinact, maximum rate of inactivation of CYP2B6 at [I] = ∞; QH, 
QPV, QHA, QINT, QMU, and QVI, are the hepatic, portal vein, hepatic artery, 
intestinal, mucosal, and villous blood flow, respectively. VH, VGW, and VPV 
are the hepatic, gut wall, and portal vein volumes.





developed parallel to the S- ketamine/norketamine model. 
These models were linked together with an interaction 
model and finally all parameters were estimated simultane-
ously using the full dataset.
Structural model
The structural model was built using a set of differential 
equations that were solved with the ADVAN13 subroutine. 
For all three substances, we commenced with a simple em-
pirical one- compartment model, and nested models were 
developed in a stepwise manner. The optimum number 
of compartments to account for drug disposition kinetics 
was optimized at first, after which the physiological com-
partments for gut wall, portal vein, and liver were added to 
the structural model.24,25 Physiological parameters incor-
porated into the model were obtained from the previously 
published studies (Table 1).
Stochastic model
The IIV on the fixed effects parameters in the model was 
specified using an exponential model:
where Φi represents the value of a fixed effect parameter for 
an individual, θ is the typical population value of the param-
eter, and ηi accounts for the IIV of the ith individual from the 
population typical value.
IIVs were first introduced with all model parameters step-
wise in nested models, and addition of each IIV parameter 
was accepted only if it lead to a significant drop in the ob-
jective function value (OFV), ε-shrinkage was <25%, and the 
model stability remained unaffected. The residual variability 
in predicted concentrations was specified with a propor-
tional error model:
where x is one of the three substances, Cij,x is the jth observed 
concentration and Ĉij,x is the model predicted concentration 
of the ith individual, and εij,x is a normally distributed random 
variable to quantify the residual variability in the concentra-
tions. Both η and ε were assumed to be normally distributed 
random variables. Additive and constant coefficient of varia-
tion models were also tested.
Model evaluation
Among nested models, a difference in the OFV was used 
to discriminate between models. A significance level of 
0.05 equaling to a drop of 3.84 points in the OFV was used. 
Standard goodness- of- fit plots26 were used to graphically 
visualize model performance. Model precision and parame-
ter identifiability were determined by assessing relative SEs 
and evaluating covariance matrices.
Prediction- corrected visual predictive checks27 (pcVPCs) 
were performed after key modeling steps by simulating 
1,000 replicates of the original study design to evaluate the 
predictive performance and model appropriateness. For 
comparison, observed data were plotted against time and 
overlaid with the 95% predictive interval of the simulated 
data.
Because of extended model estimation times, the sam-
pling importance resampling (SIR) procedure28 was used to 
evaluate parameter uncertainty and to calculate the 95% 
confidence intervals (CIs) for the parameter estimates of the 
final model. In order to get robust SIR results, the proce-
dures were run with 20,000 final samples and 2,000 resa-
mples (M/m = 10). A covariance matrix from the successful 
final model run was used as a proposal distribution. SIR re-
sults were evaluated with the graphical diagnostics methods 
in the sir- package in PsN (differences in the OFV distribution 
plot, spatial, and temporal trends plots29).
Simulations
The ncappc- package in PsN30 was used to compare model- 
predicted maximum plasma concentration (Cmax) and area 
under the curve (AUC) to the values from the NCA analysis 
from our previous report.9 Model- based simulations were 
performed using the final parameter estimates for the fixed 
and random effects in 1,000 virtual subjects with NONMEM 
to assess the performance of the mechanism- based and 
reversible components of the inhibition parameters in the 
mechanistic static model (MSM) model. These simulations 
were also used to evaluate the decrease in the intrinsic he-
patic clearances of S- ketamine during placebo and ticlopi-
dine predosing phases and the apparent recovery over time 
during inhibitor washout, and to assess the time course of 
CYP2B6 inhibition after the administration of ticlopidine, 
and the temporal recovery of enzyme activity. Finally, we 
used the final DDI model to evaluate how ticlopidine admin-
istration affects the pharmacokinetics of intravenous (i.v.) 





A one- compartment model was first tested but it 
did not capture the concentration- time course of S- 
ketamine properly. A three- compartment mammillary 
model (∆OFV = −598) with a central and two peripheral 
compartments was observed to be superior to a two- 
compartmental model (∆OFV = −578). This was consistent 
with a recent study,31 developing a population model for 
S- ketamine and norketamine after oral and i.v. dosing. 
Physiological compartments for gut wall, portal vein, and 
liver were added in a sequential manner to account for 
the disposition kinetics of S- ketamine (Figure 1) accord-
ing to the simplified quasi- steady- state approximation 
 approach25,32 (Supplementary Information S2).
Absorption profile of S- ketamine was best described 
with a simple first- order absorption rate constant (ka) 
model in comparison to a transit compartment model or 
a single Weibull absorption function. In addition, the use 
of single Weibull absorption function added a high level of 
uncertainty to the model parameters and was, therefore, 
discarded. An assumption was made that S- ketamine is 
completely metabolized to norketamine and no other me-
tabolites are involved. Thereafter, extraction at the gut wall 
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The sum of metabolic processes at the gut wall and liver 
compartments was assumed to account for both the first 
pass as well as circulatory metabolism. Both of these pro-
cesses were dependent on individually scaled blood flow lev-
els that, in turn, used the body weight as a subject specific 
parameter (Table 1). Subsequently, a portal vein compart-
ment was added to the model, and the central, hepatic, por-
tal vein, and gut wall were linked by the relevant blood flows.
The simplified quasi- steady- state approximation ap-
proach was used in the specification of differential equations 
for model specifications.25 Based on the pcVPCs, the imple-
mentation of the well- stirred model to describe the clear-
ances in the gut wall and liver sites adequately captured 
S- ketamine elimination. Our results suggest that the gut wall 
clearance of S- ketamine is very low in comparison to hepatic 
clearance, and the ratio between these two clearances was 
~1:253 (Table 2). Intestinal metabolism was implemented 
into the model assuming that the CYP- mediated S- ketamine 
metabolism takes place at the villous tips. This is supported 
by the results demonstrating the physiological distribution 
of CYP enzymes at this site.33,34 The amount of CYP2B6 
expressed in the gut wall compartment is negligible as com-
pared to the liver,34 hence, the value of intrinsic clearance at 
the gut wall found in model estimations was attributable to 
the CYP3A- based S- ketamine metabolism. According to the 
output from our model, the gut wall contributes only frac-
tionally to the total body clearance of S- ketamine.
Norketamine model
The norketamine model included a physiological gut wall, 
portal vein, and liver compartments alongside a two- 
compartment distributional model, which adequately 
Figure 1 A diagrammatic representation of the final semiphysiologically based pharmacokinetic model that includes S- ketamine 
model, norketamine model, ticlopidine model, and a dynamic drug- drug interaction model. AH, reversible component of CYP2B6 
inhibition; BH, the non- reversible component of CYP2B6 inhibition; C, central compartment; CLINT, intrinsic clearance; CYP, cytochrome 
P450; D, amount of inhibitor (ticlopidine) administered; F, bioavailability of ticlopidine into the first depot compartment; fCL′ INT,H, inhibition 
parameter signifying hepatic CYP2B6 degradation; fm,CYP2B6, fraction of S- ketamine metabolized by CYP2B6; fu, fraction unbound of 
ticlopidine in the blood; GW, gut wall; H, hepatic; [I], ticlopidine concentration at the enzyme site; [I]PV, ticlopidine concentration at 
the portal vein; ka, absorption rate constant; kdeg, the physiological degradation rate of CYP2B6 at inhibitor concentration of [I] = 0; 
KI, degradation rate of CYP2B6 at inhibitor concentration of [I]; ki, the dissociation constant of ticlopidine for CYP2B6; kinact, the 
maximal inhibition rate achieved at inhibitor concentration [I] = ∞; NK, norketamine; PER1, first peripheral compartment; PER2, second 





described norketamine disposition kinetics (∆OFV = −734), 
compared to a one- compartment model. A three- 
compartment model was tested but it did not result in a 
significantly better fit (∆OFV = −1.5) and resulted in high un-
certainty values in the added model parameters. The output 
from the well- stirred clearance model for S- ketamine at the 
gut wall and liver were used as input for the norketamine 
model and it led to a good model fit. Norketamine elimination 
was described with a well- stirred clearance model and our 
results indicate that both gut wall and liver contribute signifi-
cantly to the norketamine metabolism.
Ticlopidine model
The modeling of ticlopidine concentration- time data was 
carried out alongside S- ketamine/norketamine modeling. 
A two- compartment disposition model described the ti-
clopidine data satisfactorily and, compared to the one- 
compartment model, showed better model performance 
(∆OFV = −141). A three- compartment model could not 
be estimated reasonably and was, thus, discarded. Gut 
wall, portal vein, and liver compartments were added se-
quentially in a similar manner as to the S- ketamine model. 
Although a well- stirred clearance model was initially im-
plemented at the gut wall and liver compartments, it was 
noticed that a plausible estimate for the gut wall clearance 
could not be estimated because the timing for sample col-
lection during the early absorption phase was scarce (see 
Supplementary Information S1), and was fixed to zero. 
Thus, the gut wall acted essentially as a physiological 
transit for ticlopidine with metabolism taking place at the 
Table 2 Pharmacokinetic parameter estimates from the final model, and median parameter estimates with 95% CIs from the PsN SIR package
Parameter (unit) Description
NONMEM SIR- resultsa
Mean θ estimate %RSE Median 95% CI
S- ketamine
CLINT,H,SK (L/h) Intrinsic hepatic clearance 301 14.2 304 [260, 352]
CLINT,GW,SK (L/h) Intrinsic gut wall clearance 1.19 39.5 1.22 [0.66, 1.98]
Ka,SK (/h) Absorption rate constant 1.76 16.1 1.78 [1.47, 2.11]
VC,SK (L) Volume of central compartment 14.4 43.1 14.4 [5.90, 22.5]
VPER1,SK (L) Volume of first peripheral compartment 102 8.0 102 [92.5, 111]
QPER1,SK (L/h) Central to first peripheral compartment clearance 287 11.3 288 [250, 331]
VPER2,SK (L) Volume of second peripheral compartment 180 3.8 180 [167, 190]
QPER2,SK (L/h) Central to second peripheral compartment 
clearance
22.4 6.0 22.3 [20.8, 24.1]
IIV on CLINT,H,SK Interindividual variability on CLINT,H,SK 0.25 11.9 0.26 [0.17, 0.37]
IIV on CLINT,GW,SK Interindividual variability on CLINT,GW,SK 2.1 22.4 2.0 [1.11, 3.67]
IIV on Ka,SK Interindividual variability on Ka,SK 0.42 17.9 0.44 [0.29, 0.66]
IIV on  VPER1,SK Interindividual variability on VPER1,SK 0.045 22.3 0.046 [0.022, 0.076]
RVSK,PLAC Proportional residual error with placebo 0.086 2.1 0.086 [0.079, 0.093]
RVSK,TICLO Proportional residual error with ticlopidine 0.065 33 0.065 [0.048, 0.09]
Norketamine
CLINT,H,NK (L/h) Intrinsic hepatic clearance
b 73.5 7.8 73.4 [67.6, 79.9]
CLINT,GW,NK (L/h) Intrinsic gut wall clearance
b 44.4 35.8 46.5 [29.7, 71.2]
VC,NK (L) Volume of central compartment
b 88.4 4.8 88 [82.6, 93.5]
QPER1,NK (L/h) Central to first peripheral compartment clearance
b 19.9 12.3 20.1 [17.3, 22.8]
VPER1,NK (L) Volume of first peripheral compartment
b 88.9 5.6 88.8 [81.7, 96.5]
IIV on CLINT,H,NK Interindividual variability on CLINT,H,NK 0.10 15.1 0.10 [0.07, 0.15]
RVNK,PLAC Proportional residual error with placebo 0.062 2.4 0.062 [0.057, 0.068]
RVNK,TICLO Proportional residual error with ticlopidine 0.064 31 0.067 [0.050, 0.090]
Ticlopidine
CLINT,H,TIC (L/h) Intrinsic hepatic clearance 1505 27.9 1490 [1148, 1820]
CLINT,GW,TIC (L/h) Intrinsic gut wall clearance 0 (FIXED) – – –
Ka,TIC (/h) Absorption rate constant 3.3 (FIXED) – – –
VC,TIC (L) Volume of central compartment 50.3 13.9 50.8 [43.9, 57.7]
VPER1,TIC (L) Volume of first peripheral compartment 191 67 208.7 [130, 393]
QPER1,TIC (L/h) Central to first peripheral compartment clearance 26.3 24.4 25.8 [20.9, 32.0]
IIV on CLINT,H,TIC Interindividual variability on CLINT,H,TIC 0.12 76.2 0.13 [0.06, 0.28]
RVTICLO Proportional residual variability 0.066 9.5 0.067 [0.053, 0.083]
CI, confidence interval; GW, gut wall; H, hepatic; NK, S- norketamine; PLAC, placebo; RSE, relative standard error; SK, S- ketamine; TICLO, ticlopidine.
aSIR procedure was executed with 20,000 final proposal samples and 2,000 resamples.
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liver site only. A considerable degree of sparsity in the ti-
clopidine data during the early absorption phase was chal-
lenging for ticlopidine model development. All efforts to 
calculate the absorption rate constant (ka,TIC) freely in the 
model were unsuccessful and, therefore, ka,TIC was fixed 
to a published value of 3.3/h.8 The absorption phase was 
adequately described by a transit compartmental model. 
Transit compartments were added to the preceding gut wall 
compartment in the model in a sequential manner to op-
timize the number of transits required. We observed that 
four transit compartments adequately described the sparse 
absorption phase among the nested models (∆OFV = −36).
Repeated dosing of ticlopidine may increase the elimina-
tion half- life, indicating that ticlopidine may auto- inhibit its 
metabolism in vivo.12 Because ticlopidine is a potent inhib-
itor of CYP2B6 enzyme, which is also the enzyme respon-
sible for ticlopidine metabolism in humans, this hypothesis 
is biologically plausible. However, a potential auto- inhibition 
could not be modeled in our study and ticlopidine metabo-
lism was described as a first- order process.
Drug- drug interaction model
In vitro experiments indicate that ticlopidine causes both time- 
dependent (mechanism based) and reversible (competitive) 
inhibition of CYP2B6- mediated S- ketamine metabolism.10,14 
We attempted to model the effective amount of CYP2B6 en-
zyme remaining after ticlopidine dosing while specifying intrin-
sic hepatic clearance as a function of the amount of CYP2B6 
enzyme, but a high degree of uncertainty was noticeable in 
the model parameters. The use of a pseudo first- order enzyme 
degradation model, whereby the degradation of CYP2B6 was 
a function of the inhibitor concentration, was also unsuccess-
ful. The mechanistic static model (MSM)35 was then imple-
mented as the drug interaction model to describe the complex 
DDI between S- ketamine and ticlopidine. We assumed that 
ticlopidine administration leads to a complete cessation of 
CYP2B6- mediated N- demethylation by CYP2B6 due to a 
100% loss of enzymatic activity. This equates to an ~60% fall 
in the intrinsic hepatic clearance during the ticlopidine phase 
(fm,CYP2B6 = 0.60).
8 An inhibition parameter describing the net 
effect of ticlopidine on the intrinsic hepatic clearance was cal-
culated using a reversible and time- dependent components 
(see Supplementary Information S2):
where fCL′
INT,H
 is the inhibition parameter describing the 
fractional change in the intrinsic hepatic clearance of S- 
ketamine during the ticlopidine predosing phase, AH is 
the reversible part, BH is the time- dependent part of the 
of CYP2B6 inhibition, and fm,CYP2B6 = 0.60 is the fraction of 
S- ketamine metabolized by CYP2B6.
Next, the inhibition parameter fCL′INT,H was used to calculate 
the effect of ticlopidine- mediated CYP2B6 inhibition on the 
intrinsic hepatic clearance of S- ketamine as follows:
CLINT,H,[I] and CLINT,H,[I]=0 are the intrinsic hepatic clear-
ance of S- ketamine during the ticlopidine and placebo 
phases, respectively, and fCL′
INT,H
 is the inhibition parameter 
that accounts for the inhibition of CYP2B6 by ticlopidine. 
Gut wall clearances of S- ketamine and norketamine were 
fixed to the population values from placebo phase data as-
suming that these would remain unchanged during ticlopi-
dine phase.
The MSM model resulted in a good fit and suggested a 
very strong inhibitory effect of ticlopidine on S- ketamine 
metabolism. A 63% inhibition of S- ketamine metabolism re-
sulted in the lowest OFV, which is in accordance with the 
result from a recent in vitro study.8 Log likelihood- profiling 
confirmed the results (Supplementary Information S2). The 
final model is depicted in Figure 1.
Model evaluation
The final drug interaction model resulted in a good 
fit for S- ketamine at the ticlopidine predosing phase. 
The model converged with successful minimization and 
a functional covariance matrix, with plausible param-
eter estimates that had reasonably low SEs (Table 2). 
Goodness- of- fit plots showed an acceptable fit, although 
for norketamine there are slight trends visible during the ti-
clopidine phase (Figure S2). The pcVPCs indicate a good 
predictive performance and confirmed the model appro-
priateness (Figure 2), but some subjects showed obvi-
ous underprediction of norketamine during the inhibitor 
phase.
Further evaluation of the model was performed with the 
SIR procedure. The final parameters were close to the me-
dian of SIR values (Table 2) and nonparametric 95% CIs 
obtained through the SIR procedure were also in good 
agreement with the CIs calculated from NONMEM produced 
SEs.
Simulations
The ncappc- package was used to simulate AUC values 
during different phases of S- ketamine dosing. Our results 
indicate that ticlopidine predosing can cause more than a 
twofold rise in S- ketamine AUC in humans, which is con-
sistent with previous NCA analysis and in vitro results9 
(Table 3). Ticlopidine profoundly inhibited CYP2B6 activity 
and the final DDI model was used to simulate the effect 
of ticlopidine on the parameters describing the fractional 
inhibition of intrinsic hepatic clearance, the change in the 
intrinsic hepatic clearance during placebo and inhibitor 
phase, and the percentage of remaining CYP2B6 activity 
(%RA). The remaining CYP2B6 activity was calculated as 
follows:
where AH is the reversible and BH is the time- dependent 
part of inhibition, and Activity[I] = 0 is the activity at placebo 
phase (i.e., numerically assumed to be 100%).
The results from these simulations show that the initial 
drop in the intrinsic hepatic clearance, which resembles 
an “on- off” phenomenon is followed by a dynamic phase, 
which demonstrates the slow recovery of enzyme activity 
and consequently a rise in CLINT,H (Figure 3a). The recov-
ery seems to level off as ticlopidine is dosed further during 
fCL�
INT,H








the predosing phase, until a steady state is reached near 
the last ticlopidine dose. After the final ticlopidine dose, 
the enzyme activity and intrinsic hepatic clearance start 
to recover quickly and reach the initial levels ~4–5 days 
after the final inhibitor challenge (Figure 3b). Simulation 
of S- ketamine plasma concentrations after oral dosing 
(25 mg, t.i.d.) after ticlopidine predosing demonstrated a 
high exposure of S- ketamine immediately following the ti-
clopidine predosing (Figure 3c). The exposure decreases 
slowly after ticlopidine has been washed out and intrinsic 
hepatic clearance recovers to the baseline levels. The ef-
fect of ticlopidine predosing is less pronounced on the 
i.v. S- ketamine administration (5 mg t.i.d. after ticlopidine 
predosing 250 mg b.i.d. for 6 days). This can be attributed 
to the lack of first- pass metabolism in this route of admin-
istration. However, an accumulation of S- ketamine can be 
clearly seen, which wears off as ticlopidine is washed out 
(Figure 3d).
DISCUSSION
We have used previously collected in vivo data to develop 
a semimechanistic model to describe the pharmacoki-
netic profile of S- ketamine and its metabolite norketamine 
simultaneously. Three- compartment mammillary model 
and a two- compartment model were successfully linked 
to physiological compartments representing the gut wall, 
portal vein, and liver for S- ketamine and norketamine, re-
spectively. A semimechanistic model for ticlopidine phar-
macokinetics that included four transit compartments, and 
a two- compartment distributional model in conjunction 
with the gut wall, portal vein, and liver compartments was 
built following the modeling strategy described earlier24 
and added to the S- ketamine/norketamine model. Finally, 
S- ketamine and ticlopidine models were linked together 
with MSM describing the mechanism- based inhibition of 
S- ketamine metabolism by ticlopidine. Model evaluation 
Figure 2 Prediction- corrected visual predictive checks obtained from 1,000 simulations stratified on compound and study phase 
showing S- ketamine and norketamine after oral administration of 0.2–0.3 mg/kg S- ketamine during placebo phase (a and b, 
respectively), during ticlopidine predosing phase (c and d, respectively), and ticlopidine after oral ticlopidine administration of 250 mg/
day b.i.d. for 6 days (e). Circles show the observed concentrations, solid lines the median and dashed lines the 2.5th and 97.5th 
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with visual predictive checks and the sampling importance 
resampling- procedure demonstrated that the model pa-
rameters were accurate and precise.
Our results indicate that the administration of ticlopi-
dine led to a markedly low intrinsic hepatic clearance of S- 
ketamine (from 304 L/hour at placebo phase to 113 L/hour), 
whereas the total hepatic clearance was much less affected 
(from 71 L/hour at placebo phase to 60 L/hour). This obser-
vation is typical for high extraction ratio drugs when using 
the well- stirred clearance model.36 Another significant find-
ing was the minor role of gut wall clearance in the overall 
S- ketamine metabolism, as the ratio of gut wall to hepatic 
clearance was 1:253. Dense sampling after S- ketamine dos-
ing allowed us to model the gut wall clearance with a low un-
certainty level. CYP3A4 has been proposed in the literature 
as the major enzyme responsible for S- ketamine demethyl-
ation to norketamine,37 but our results demonstrate that the 
gut wall clearance is not an important player in S- ketamine 
biotransformation, suggesting that CYP3A contribution to S- 
ketamine metabolism is lesser than previously anticipated. 
Gut wall expression of CYP2B6 is negligible,33 therefore, the 
contribution of gut wall to total clearance can be attributed 
to the intestinal CYP3A4 reservoir only. These findings have 
been further emphasized by a recent study that showed that 
CYP2B6*6 allele in human liver microsomes and cos- 1 ex-
pressed CYP2B6 protein variants resulted in a considerable 
decrease of S- ketamine metabolism.38 Although the gut 
wall has been documented to play a major role in the over-
all clearance of xenobiotics from the human body, it has to 
be noted that the role of gut- wall CYP enzyme reservoirs is 
limited to first- pass drug metabolism only, and do not impart 
a challenge to the unchanged drug fraction in the systemic 
circulation.39 Hence, the role of gut wall clearance is import-
ant only for the oral route of drug administration and is insig-
nificant in vascular drug delivery.
Although S- ketamine has several metabolites in vivo, nor-
ketamine accounts for 80% of the metabolites.3,6 During the 
model development, we assumed that the extraction of S- 
ketamine in the gut wall and liver compartments generates 
norketamine as the sole metabolite. The pharmacokinetic 
models for both of these substances demonstrated adequate 
precision and provided a good model fit. Our results indicate 
that the both gut wall and liver contribute significantly to nor-
ketamine metabolism to 6- hydroxy- norketamine (Table 2), 
which has been previously reported to take place rapidly.37 
Norketamine elimination was described with a well- stirred 
clearance model at both elimination sites. The assumption 
that S- ketamine is metabolized only to norketamine is biolog-
ically plausible, because ~80% of S- ketamine is metabolized 
to norketamine in vivo. The output from the well- stirred clear-
ance model for S- ketamine could, therefore, be used as an 
input for the norketamine model, and it led to a good model fit.
A slight trend in the norketamine model fit at the inhibitor 
phase can be attributed to the fast metabolism to secondary 
metabolites, but also to the marked between- subject vari-
ability in the S- ketamine metabolism. Previous results indi-
cate that norketamine is readily metabolized by CYP2B6 to 
a secondary metabolite.37 Although any significant change 
in norketamine profile after ticlopidine pretreatment was 
not documented,9 an inhibition of this metabolic pathway 
in vivo can cause an increase in norketamine AUC without 
affecting the maximum plasma concentrations, as shown 
by the model output. A metabolic inhibition model for the 
metabolite could not be implemented due to a lack of in-
formation about the metabolite parameters needed for the 
MSM. Furthermore, the mechanistic- static model is formu-
lated to be dependent only on the inhibitor concentration 
in the portal vein and not on the CYP- enzyme levels, which 
are assumed constant across individuals. Therefore, the 
between- subject variability could only be accounted for the 
portal vein inhibitor concentrations.
A well- stirred clearance model for ticlopidine was initially 
implemented in the gut wall and liver compartments, but the 
resulting fit showed that a plausible estimate for gut wall 
clearance could not be estimated. This is most likely due 
to the scarce sampling during the early absorption phase 
after ticlopidine dosing. After testing several absorption 
models, we implemented a transit- compartmental model, 
which provided an adequate fit. Some reports indicate that 
repeated ticlopidine dosing causes an increase in its half- life 
Table 3 Comparison of the noncompartmental analysis (NCA) results from Peltoniemi et al.9 and the final semimechanistic pharmacokinetic model based 
on simulations with ncappc package in PsN30
Compound PK parameter
S- ketamine
p.o. placebo- phase i.v. placebo- phase p.o. ticlopidine- phase
NCA resultsa
S- ketamine AUC (ng h/mL) 21 76 54
Cmax (ng/mL) 9.9 32 17
Norketamine AUC (ng h/mL) 292 121 310
Cmax (ng/mL) 61 14 46
Model predictionsb
S- ketamine AUC (ng h/mL) 22.4 70 53.2
Cmax (ng/mL) 9.37 41 18.1
Norketamine AUC (ng h/mL) 279 161 250
Cmax (ng/mL) 56 22 45
AUC, area under the curve; Cmax, peak plasma concentration; NCA, noncompartmental analysis.
aAUC calculated by trapezoidal rule with extrapolation to infinity.





suggesting an auto- inhibition process.12 These findings are 
physiologically plausible due to the marked potential of ti-
clopidine to inhibit CYP2B6. We evaluated an auto- inhibition 
of hepatic ticlopidine metabolism, but our attempts were un-
successful, probably owing to the design of the original DDI 
study. Thus, the phenomena could not be supported with 
the current data.
The mechanistic- static model35 allowed us to model 
the mechanism- based DDI between S- ketamine and ti-
clopidine. The MSM uses inhibitor concentration at the 
portal vein along with the enzyme inhibition constants 
(i.e., kinact, KI, and ki) to dynamically account for the en-
zyme inhibition, resulting in a fractional parameter that 
describes the reduction in the S- ketamine intrinsic hepatic 
clearance during the presence of an inhibitor. The enzyme 
parameters have been previously determined in in vitro 
studies,11 and, therefore, our model demonstrates an ex-
ample of in vitro-in vivo correlation models; a predictive 
mathematical model describing the relationship between 
in vitro property of an oral dosage form and relevant in 
vivo response.40
Ticlopidine is a strong mechanism- based inhibitor of 
CYP2B6 in the liver and its enzyme constants imply that 
a very low ticlopidine concentration is required to cause a 
marked loss of CYP2B6 activity.11 Consistent with these 
findings, our model indicates a complete loss of CYP2B6 
activity following the first dose, resembling an “on- off” phe-
nomena rather than a dynamic concentration- dependent 
Figure 3 Simulation results. (a) The intrinsic hepatic clearance (sky- blue) of S- ketamine demonstrates the same pattern of a sudden 
drop, which attains a steady state during ticlopidine dosing, and then recovers quickly during the ticlopidine washout. The black arrows 
show ticlopidine dosing. (b) The percentage remaining activity (%RA) of cytochrome P450 (CYP)2B6 (green) immediately before, during 
and after ticlopidine dosing. Ticlopidine portal vein concentration is shown in orange. The %RA was calculated using the reversible 
and time- dependent components of the mechanistic static drug- drug interaction model. A sharp fall in %RA upon ticlopidine dosing 
resembles an “on- off” phenomenon, however, the inset graph shows that the inhibition process is dynamically captured by the model 
during the inhibitor pretreatment and the inhibitor concentration required to cause a complete enzyme degradation is very low. The 
activity is completely recovered ~4–5 days after last ticlopidine dose. (c) The S- ketamine plasma concentrations (blue) after oral 
dosing (25 mg, t.i.d.) after ticlopidine pre- dosing (250 mg b.i.d. for 6 days). Ticlopidine plasma concentrations are shown in yellow. 
High exposure of S- ketamine is noticeable immediately following the ticlopidine predosing, which drops slowly after ticlopidine has 
been washed out and intrinsic hepatic clearance recovers to the baseline levels. (d) S- ketamine plasma concentrations (blue) after i.v. 
dosing (5 mg t.i.d.) after ticlopidine predosing (250 mg b.i.d. for 6 days). The effect of ticlopidine predosing is less pronounced on the 
i.v. S- ketamine administration. This can be attributed to the lack of first- pass metabolism in this route of administration. However, an 
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inhibition. However, our simulations indicate that ticlopidine 
shows a concentration- dependent inhibition (Figure 3b), but 
already a very low concentration of ticlopidine is capable 
of causing complete inactivation of the CYP2B6 pool in the 
liver. Our results suggest that a complete recovery of the 
CYP2B6 enzyme activity takes place only after ~4–5 days 
after the last ticlopidine challenge. As can be anticipated, 
the enzyme activity is linearly correlated with the intrinsic 
hepatic clearance, which is also seen to gradually rise back 
to the normal levels once ticlopidine has been washed out 
(Figure 3).
Our model has several limitations. Many assumptions of 
underlying processes had to be made and certain parame-
ters were fixed during the model development phase. The 
models had to be developed in a way that would provide ad-
equate fits while avoiding overparameterization at all stages. 
A number of limitations for model development came from 
the data at hand, which included a small sample size during 
the inhibitor phase, as well as sparsely sampled ticlopidine 
absorption. However, these limitations were successfully 
covered during model development and the final model 
shows clinically plausible parameter estimates.
In conclusion, our final model adequately predicts the 
DDI between S- ketamine and ticlopidine, indicating a 
mechanistic basis of CYP2B6 inhibition by ticlopidine, 
and establishing the utility of “mechanistic- static model” 
in DDI modeling. The use of in vitro results in population 
modeling in a semimechanistic system demonstrates a 
useful method to account for mechanism- based DDIs in a 
dynamic concentration- dependent manner. In comparison 
to a conventional NCA, this approach provides a dynamic 
framework with temporally varying inhibitor concentra-
tions for driving DDI model equations, alongside enzyme 
inhibition constants previously reported in in vitro studies.
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